Endpoints@JPM: (left to right) Steve Pearson, Nick Leschly, Bari Talente, Stephen Ubl, John Carroll

January 14, 2020 11:00 AM ESTUpdated January 16, 04:07 AM

#JPM20: 'The NPV is always wrong.' Takeda preps another spinout — this time on psych

Jason Mast

Editor

Editor’s Note: Endpoints News is reporting live from #JPM20 after kicking things off with an action-packed event, which you can replay here. What follows …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#JPM20: 'The NPV is always wrong.' Takeda preps another spinout — this time on psych

Jason Mast

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China startup injects CRISPR therapy into the brain for the first time

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Roivant brings rare disease program closer as Immunovant CEO retires

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

#JPM20: 'The NPV is always wrong.' Takeda preps another spinout — this time on psych